Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 15/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.58 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.58 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32682813 | 1.00 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL5359084 | 0.84 | GRIA2 (0.73) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL6505317 | 0.84 | GRIA2 (0.72) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL5184614 | 0.82 | GRIA2 (0.70) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL6494353 | 0.82 | GRIA2 (0.70) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL6504948 | 0.82 | GRIA2 (0.70) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL2778320 | 0.82 | GRIA2 (0.69) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL28423069 | 0.80 | GRIA2 (0.67) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL6413657 | 0.80 | GRIA2 (0.67) | GRIA2 | |
| SCHEMBL5418711 | 0.78 | GRIA2 (0.64) | GRIA2CA1CA2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | GRIA2 60/4885GRIA1 46/4885GRIA3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.